By Dr. Asnat Raziel, bariatric surgeon specializing in obesity treatment, metabolic health and healthy longevity; Director of the Multidisciplinary Center for Obesity Treatment, Assia Medical, Assuta Ramat HaChayal, Tel Aviv
Wegovy pill vs injection: what is the question?
Wegovy pill vs injection is one of the most common questions I hear in my clinic today. For years, we knew Wegovy as a weekly injection. Now semaglutide has entered a new stage: a daily pill for treating obesity. The OASIS 4 trial showed meaningful weight loss with oral semaglutide at 25 mg. In addition, a 2026 comparative analysis examined how closely those results match the 2.4 mg Wegovy injection.
Meanwhile, the pill is already on the market. The U.S. Food and Drug Administration (FDA) approved the Wegovy pill on December 22, 2025. The approval covers weight loss, keeping the weight off and lowering the risk of major heart events. Then, on July 15, 2026, the European Commission approved the pill for adults with a BMI of 30 or more, or 27 or more with a weight-related condition. I answer common questions about the new pills in my article on weight-loss pills.
The OASIS 4 trial: a 25 mg semaglutide pill
The OASIS 4 trial enrolled 307 adults without diabetes. All of them had a BMI of 30 or more, or 27 or more with a weight-related condition. The researchers randomly assigned them to oral semaglutide 25 mg or a placebo, once a day. In addition, every participant received lifestyle counseling.
After 64 weeks, weight fell by an average of 13.6% with the pill, compared with 2.2% on placebo. This analysis included everyone, even people who stopped treatment. By contrast, among those who stayed on treatment, weight loss reached 16.6%, versus 2.7% on placebo. Moreover, according to the manufacturer, one in three people who stayed on the pill lost 20% or more of their body weight.
Beyond the scale, the researchers found better physical function and quality of life. Side effects were mainly digestive, just as with the injection. For example, digestive symptoms occurred in 74.0% of people on the pill, compared with 42.2% on placebo. In most cases they were mild to moderate and eased over time. You can find a full review in my article on Wegovy side effects.
The Wegovy injection: the STEP 1 trial
The STEP 1 trial enrolled 1,961 adults with obesity or overweight and no diabetes. After 68 weeks, weight fell by 14.9% with the weekly 2.4 mg Wegovy injection, compared with 2.4% on placebo. Among those who stayed on treatment, the average loss was 16.9%.
In addition, 86.4% of patients lost at least 5% of their weight. Furthermore, 69.1% lost at least 10%, and 50.5% lost at least 15%. These numbers turned the injection into a milestone in obesity medicine.
Wegovy pill vs injection: the indirect comparison
No trial has randomly assigned patients to the pill or the injection. That is why a study published in June 2026 in the journal Diabetes, Obesity and Metabolism ran an indirect comparison of OASIS 4 and STEP 1. Researchers call this method an ITC, or indirect treatment comparison. Put simply, it compares two trials through their placebo groups.
The two trials are very similar. Starting weight and BMI were alike, neither trial included people with diabetes, and both combined treatment with lifestyle changes. The results are striking:
- Across all participants: 13.6% weight loss with the pill, versus 14.9% with the injection.
- Among those who stayed on treatment: 16.6% with the pill, versus 16.9% with the injection.
In other words, the raw gap is only 1.3 percentage points, and just 0.3 points among those who stayed on treatment. In the statistical analysis itself, the injection had a small numerical edge: 1.01 percentage points in the first analysis and 0.55 in the on-treatment analysis. However, the confidence intervals of both differences included zero, so there was no significant difference. In addition, the gap is far below the 5% threshold the FDA considers clinically meaningful. Likewise, the chance of losing 5%, 10%, 15% or 20% of body weight was similar.
Is the Wegovy pill as effective as the injection?
The data suggest that oral semaglutide 25 mg delivers efficacy in the same range as the 2.4 mg Wegovy injection. Still, it is important to be precise. This is an indirect comparison of two trials, not a head-to-head study. Also, employees of Novo Nordisk, the maker of both drugs, were among the authors of the analysis.
So we can say the results look very similar. Even so, we cannot yet say that studies have proven the two forms fully equivalent. It is also worth remembering that the injection itself has evolved. Today there is a higher 7.2 mg dose, which leads to much greater weight loss than 2.4 mg. The ITC looked only at the 2.4 mg dose.
How is it different from Rybelsus?
Rybelsus also contains semaglutide in pill form. However, the doses and the approved uses are different. Rybelsus has approval for type 2 diabetes, whereas the Wegovy pill, at 25 mg once a day, has approval for treating obesity. So this is not simply Rybelsus under a new name. Rather, it is a different treatment framework, with a different dose and a different goal. I compare them in detail in my article on Rybelsus vs the Wegovy pill.
Wegovy pill vs injection: how do you choose?
Having an effective treatment in pill form greatly widens our options. Some patients prefer a pill and do not want to inject. The emotional side of treatment matters too, as I explain in my article on weight loss drugs and emotions. On the other hand, you must take the pill every day, and the instructions matter. As with Rybelsus, you take it on an empty stomach and wait before eating. By contrast, you take the injection only once a week.
For example, Israel Hayom’s report on the FDA approval notes that you should not eat or drink for 30 minutes after taking the pill.
If the efficacy really is similar, the choice comes down to what suits each person. The factors include patient preference, adherence, lifestyle, side effects, price and availability. If you are thinking about moving from the injection to the pill, you will find practical advice in my article on switching from the injection to the pill. I also compare it with another pill in my article on the Wegovy pill and Foundayo.
The bottom line
Wegovy pill vs injection is no longer just a theoretical question. Regulators in the United States and in Europe have approved both forms, and the indirect comparison points to very similar efficacy. Nevertheless, final proof will come only from a head-to-head trial. Ultimately, you make the right choice together with your doctor, based on each person’s goals, habits and health.
This article provides general information and is not a substitute for personal medical advice.
References
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Novo Nordisk A/S: Wegovy pill approved in the US as first oral GLP-1 for weight management
The studies were funded by Novo Nordisk, the manufacturer of the drug.
